Launch week offerEnds in00h00m00s

annual Promonthly Pro

Rohit Joshi

University of South Australia

Australia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Australia

Articles (11)

Year:

2026

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

David Beale

Commonwealth Scientific and Industrial Research Organisation

AUSTRALIA

View details

Feargal Ryan

Head, Computational Multi-Omics

Flinders University

AUSTRALIA

View details

Courtney Cross

University of Adelaide

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rohit Joshi

Research Interests

Make your next move.

Explore related searches

Articles (11)

Pre-treatment gut microbiome and salivary metabolome signatures associate with chemotherapy-induced cognitive decline in women with breast cancer: A prospective pilot study

The Impact of Combined Chemotherapy and Intra-Tumoural Injection of Phosphorus-32 Microparticles on Vascularity in Locally Advanced Pancreatic Carcinoma

A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC.

Safety and clinical activity of target-preserving anti-CTLA-4 antibody ONC-392 as monotherapy in NSCLC patients who progressed on PD(L)1-targeted immunotherapy.

Abstract CT050: A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC

Abstract OT2-10-01: A phase 2, randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer

564 Safety and clinical activities of the acid pH-sensitive anti-CTLA-4 mAb ONC-392 in ovarian cancer patients

632 Clinical update from a phase 1, first-in-human, open-label single agent study of SUPLEXA therapeutic cells in patients with metastatic solid tumours and haematologic malignancies

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).

CSCO breast cancer management guidelines 2022: Australian perspective

A Prospective Audit of Inpatient Medical Oncology Consultation Patterns in a Tertiary Teaching Hospital in South Australia

Collaborators (3)

David Beale

Feargal Ryan

Courtney Cross

Make your next move.